Fair Game: Valeant’s High-Price Drug Strategy

Valeant, which has grown by acquiring rivals and slashing their staffs, has drawn the ire of a House panel, which is now considering a subpoena on the company’s price increases.











from NYT > Health http://ift.tt/1RlIkbu
via health&fitness